SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...
Barclays analyst Peter Lawson maintained a Buy rating on Immunocore Holdings (IMCR – Research Report) today and set a price target of $66.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback